Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 20Recruiting 19Completed 17Terminated 9Withdrawn 6Not yet recruiting 6Unknown 5Suspended 1No longer available 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 20Genitourinary 19Gastrointestinal 16Dermatologic 15Breast 13Head & Neck 12Lymphoid 7Plasma cell 6CNS 6Gynecologic 5Sarcoma 4Other hematologic neoplasm 4Tumor-Agnostic 2Other solid neoplasm 2Endocrine 1

Conditions

Brain Neoplasms 3Glioblastoma 2Triple Negative Breast Neoplasms 1Glioma 1Central Nervous System Diseases 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Temozolomide 19Magnetic Resonance Spectroscopy 16Radiosurgery 12Bevacizumab 12Radiotherapy 10Radiation 8pembrolizumab 6Specimen Handling 6Methotrexate 6Surgical Procedures, Operative 5Topotecan 4TIC10 compound 4Isotretinoin 4Carmustine 4Carboplatin 4abemaciclib 3Trastuzumab 3Thiotepa 3Standard of Care 3Nivolumab 3Magnetic Resonance Imaging 3Lomustine 3Irinotecan 3Erlotinib Hydrochloride 3Drug Therapy 3Dexamethasone 3vandetanib 2thymoglobulin 2temsirolimus 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × pembrolizumab × CNS × Clear all
NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT04118036 2025-08-11

Abemaciclib + Pembrolizumab In Glioblastoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
CNS

Glioblastoma

NCT05879120 2024-11-20

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNS

Glioblastoma

NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Washington University School of Medicine

Phase 2 Withdrawn
BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT04512261 2022-07-01

TOPAZ

Cedars-Sinai Medical Center

Phase 1/2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

NCT04220892 2020-07-31

Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma

Saint John's Cancer Institute

Phase EARLY_PHASE1 Withdrawn
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡